Long-term study of people with HIV taking long-acting injectable medicines
Collects health and lab data from adults with HIV receiving cabotegravir and rilpivirine injections.
Plain-language title generated from the registry record
Registry title: Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- Ospedale San Raffaele Scientific InstituteMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Castagna Antonella
- Trial code
- NCT05663580
- Record updated
- 19 October 2026
- Original description
Systematic, continuative collection of clinical and laboratory data on patients followed at lnfectious Diseases Unit of the IRCCS San Raffaele Hospital in Milan, receiving long-acting ART (Phase IV, single-center, prospective, cohort study)Read full original descriptionShow less
Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy (SCohoLART)
Systematic, continuative collection of clinical and laboratory data on patients followed at lnfectious Diseases Unit of the IRCCS San Raffaele Hospital in Milan, receiving long-acting ART (Phase IV, single-center, prospective, cohort study)
PRIMARY ENDOPOINT: Treatment failure over 48 weeks, defined as virological failure (VF) or therapy discontinuation for any reason (TD)
SECONDARY ENDPOINTS:
Clinical and pharmacological determinants of efficacy, tolerability, toxicity Modifications in risk and incidence of comorbidities Description of drug-resistance in case of VR Efficacy of rescue regimens in case of VF Quality of life and patient's satisfaction
Inclusion: HIV infection; Age > 18 years; HIV-RNA <50 copies/ml; Stable ART; Planned start of a long-acting regimen approved by AIFA (initially, cabotegravir and rilpivirine); Written informed consent provided.
Exclusion: Any contraindication to the use of one or more long-acting drug, according to the technical sheet of the long-acting drug(s) planned to be started (including pregnancy, current or planned).